Pubblicazioni

Autori:

Vitale, Antonio; Cavalli, Giulio; Colafrancesco, Serena; Priori, Roberta; Valesini, Guido; Argolini, Lorenza Maria; Baldissera, Elena; Bartoloni, Elena; Cammelli, Daniele; Canestrari, Giovanni; Sota, Jurgen; Cavallaro, Elena; Massaro, Maria Grazia; Ruscitti, Piero; Cipriani, Paola; De Marchi, Ginevra; De Vita, Salvatore; Emmi, Giacomo; Ferraccioli, Gianfranco; Frassi, Micol; Gerli, Roberto; Gremese, Elisa; Iannone, Florenzo; Lapadula, Giovanni; Lopalco, Giuseppe; Manna, Raffaele; Mathieu, Alessandro; Montecucco, Carlomaurizio; Mosca, Marta; Piazza, Ilaria; Piga, Matteo; Pontikaki, Irene; Romano, Micol; Rossi, Silvia; Rossini, Maurizio; Silvestri, Elena; Stagnaro, Chiara; Talarico, Rosaria; Tincani, Angela; Viapiana, Ombretta; Vitiello, Gianfranco; Galozzi, Paola; Sfriso, Paolo; Gaggiano, Carla; Rigante, Donato; Dagna, Lorenzo; Giacomelli, Roberto; Cantarini, Luca

Titolo:

Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response

Anno:

2019

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

FRONTIERS IN PHARMACOLOGY

ISSN Rivista:

1663-9812

N° Volume:

10

Intervallo pagine:

296-297

Parole chiave:

autoinflammatory diseases; canakinumab; innovative biotechnologies; interleukin-1; personalized medicine; systemic onset juvenile idiopathic arthritis

Breve descrizione dei contenuti:

Background: Anakinra (ANA) is an effective treatment choice in patients with adult onset Still's disease (AOSD). Variables affecting treatment survival include loss of efficacy or adverse events, but also the decision to discontinue treatment after long-term clinical remission.Objectives: Aims of this study were: (i) to assess the drug retention rate (DRR) of ANA during a long-term follow-up looking for any difference related to the line of biologic treatment, the concomitant use of conventional disease modifying anti-rheumatic drugs cDMARDs) and the different type of AOSD (systemic versus chronic articular); (ii) to identify predictive factors of lack of efficacy, loss of efficacy, and ANA withdrawal owing to long-term remission.Methods: AOSD patients classified according with Yamaguchi criteria and treated with ANA were retrospectively enrolled in 18 Italian tertiary Centers. Demographic, laboratory, clinical and therapeutic data related to the start of ANA (baseline), the 3-month assessment and the last follow-up visit while on ANA treatment were retrospectively collected and statistically analyzed.Results: One hundred and forty-one AOSD patients (48 males, 93 females) treated with ANA for a mean period of 35.96 +/- 36.05 months were enrolled. The overall DRR of ANA was 44.6 and 30.5% at the 60- and 120-month assessments, respectively, with no significant differences between: (i) biologic naive patients and those previously treated with other biologics (log-rank p = 0.97); (ii) monotherapy and concomitant use of cDMARDs (log-rank p = 0.45); (iii) systemic and chronic articular types of AOSD (log-rank p = 0.67). No variables collected at baseline could predict primary inefficacy, while the number of swollen joints at baseline was significantly associated with secondary inefficacy (p = 0.01, OR = 1.194, C.I. 1.043-1.367). The typical AOSD skin rash was negatively related with ANA withdrawal owing to long-term remission (p = 0.03, OR = 0.224, C.I.0.058-0.863).Conclusion: Long-term DRR of ANA has been found excellent and is not affected by different lines of biologic treatment, concomitant use of cDMARDs, or type of AOSD. The risk of losing ANA efficacy increases along with the number of swollen joints at the start of therapy, while the typical skin rash is a negative predictor of ANA withdrawal related to sustained remission.

Id prodotto:

111283

Handle IRIS:

11562/1005589

ultima modifica:

12 novembre 2022

Citazione bibliografica:

Vitale, Antonio; Cavalli, Giulio; Colafrancesco, Serena; Priori, Roberta; Valesini, Guido; Argolini, Lorenza Maria; Baldissera, Elena; Bartoloni, Elena; Cammelli, Daniele; Canestrari, Giovanni; Sota, Jurgen; Cavallaro, Elena; Massaro, Maria Grazia; Ruscitti, Piero; Cipriani, Paola; De Marchi, Ginevra; De Vita, Salvatore; Emmi, Giacomo; Ferraccioli, Gianfranco; Frassi, Micol; Gerli, Roberto; Gremese, Elisa; Iannone, Florenzo; Lapadula, Giovanni; Lopalco, Giuseppe; Manna, Raffaele; Mathieu, Alessandro; Montecucco, Carlomaurizio; Mosca, Marta; Piazza, Ilaria; Piga, Matteo; Pontikaki, Irene; Romano, Micol; Rossi, Silvia; Rossini, Maurizio; Silvestri, Elena; Stagnaro, Chiara; Talarico, Rosaria; Tincani, Angela; Viapiana, Ombretta; Vitiello, Gianfranco; Galozzi, Paola; Sfriso, Paolo; Gaggiano, Carla; Rigante, Donato; Dagna, Lorenzo; Giacomelli, Roberto; Cantarini, Luca, Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response «FRONTIERS IN PHARMACOLOGY» , vol. 10 , 2019 , pp. 296-297

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo